Dallas, TX -- (SBWIRE) -- 01/19/2011 -- Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth
Small molecule targeted therapies represent a highly lucrative class of anticancer therapies with 12 drugs currently approved for various tumor types. This promise of high commercial rewards has driven considerable pipeline activity for small molecule targeted therapies within cancer.
Scope
Examination of the small molecule targeted cancer therapies pipeline with in-depth clinical and commercial profiles of Phase III candidates
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions
Segmentation and analysis of the current small molecule targeted cancer therapies pipeline by developmental phase, drug target and company
Insight and analysis of market potential including commercial opportunity and discussion of unmet needs
Highlights
There are currently 288 small molecule targeted therapies in development for cancer. Single-target signal transduction inhibitors and multi-targeted inhibitors form the majority of the pipeline, accounting for 28% and 28% of the pipeline, respectively. These two classes each contain a number of agents with novel mechanisms of action.
Progress in understanding of how to target tyrosine kinases with small molecules has benefited oncology drug discovery. Efforts are continuing to develop small molecule inhibitors against other kinases that are more selective and capable of overcoming drug resistance. Around 30 distinct targets are currently being tested in Phase I clinical trials.
The late-phase small molecule therapies directed towards novel targets are forecast to generate sales of $3,635m by 2019 across the seven major markets. Abiraterone (Cougar Biotechnology/Johnson & Johnson) and BSI-201 (BiPar Sciences/Sanofi-Aventis) are forecast to achieve the highest sales by 2019.
Reasons to Purchase
Identify key drugs and companies within the small molecule targeted cancer therapies pipeline based on sales forecasts and
Datamonitor drug assessment
Assess the shifting small molecule targeted cancer therapies market dynamic and how future treatment will incorporate pipeline products
Identify licensing opportunities based on company portfolio and market needs
Buy Now : Market Research
http://www.reportsnreports.com/
Related Reports
Pipeline Insight: Biologic Targeted Cancer Therapies - Next generation jostles for market position
Pipeline Insight: Prostate Cancer Molecular targeted therapies will fulfill unmet needs in castration-resistant disease
Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still needed
Commercial Insight: Molecular Targeted Cancer Therapies
Forecast Insight: Top 20 Cancer Therapy Brands Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy
Cancer Targeted Therapies and Immunotherapies Market Forecast
Stakeholder Opinions: Gastric Cancer - Targeted therapies compete for first-to-market status
About ReportsnReports
ReportsnReports comprises of an online library of 50,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients.